Assembly Biosciences (ASMB) Issues Quarterly Earnings Results

Assembly Biosciences (NASDAQ:ASMB) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.01) by $0.14, MarketWatch Earnings reports. The company had revenue of $4.29 million during the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%.

Shares of Assembly Biosciences stock traded down $2.19 on Friday, reaching $23.40. The stock had a trading volume of 193,657 shares, compared to its average volume of 168,602. Assembly Biosciences has a fifty-two week low of $20.61 and a fifty-two week high of $67.36. The stock has a market capitalization of $585.27 million, a price-to-earnings ratio of -9.71 and a beta of 1.43.

In other news, VP Uri A. Lopatin sold 15,204 shares of the business’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $40.09, for a total value of $609,528.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.20% of the stock is currently owned by insiders.

Several analysts have commented on ASMB shares. Robert W. Baird started coverage on shares of Assembly Biosciences in a research report on Wednesday, August 8th. They issued an “outperform” rating and a $74.00 target price for the company. Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 13th. B. Riley upgraded shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a research note on Monday, October 8th. Finally, ValuEngine cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 3rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Assembly Biosciences presently has an average rating of “Hold” and a consensus target price of $62.60.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2018/11/10/assembly-biosciences-asmb-issues-quarterly-earnings-results.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Story: What is insider trading?

Earnings History for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply